Phase Ia Study of Anti-NaPi2b Antibody-Drug Conjugate Lifastuzumab Vedotin DNIB0600A in Patients with Non-Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer.

David E GerberJeffrey R InfanteMichael S GordonSarah B GoldbergMiguel MartinEnriqueta FelipMaria Martinez-GarcíaJoan H SchillerDavid R SpigelJulie CordovaValerie WestcottYulei WangDavid S ShamesYounJeong ChoiRobert KahnRandall C DereDivya SamineniJian XuKedan LinKatie WoodStephanie Royer-JooVanessa LemahieuEva SchuthAnjali VazeDaniel MaslyarEric W HumkeHoward A Burris

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)

LIFA exhibited dose-proportional pharmacokinetics and an acceptable safety profile, with encouraging activity in patients with PROC at the single-agent RP2D of 2.4 mg/kg.

Keyphrases

hodgkin lymphoma
cancer therapy
drug delivery